Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19128887 | 0.72 | CA1 (0.41) | GAAALDH1A1 | |
| SCHEMBL19128517 | 0.71 | ELANE (0.44) | GAAALDH1A1 | |
| SCHEMBL20448940 | 0.64 | GAA (0.46) | AHRTSHRGAAALDH1A1 | |
| SCHEMBL15825111 | 0.64 | GAA (0.38) | AHRTSHRGAAALDH1A1 | |
| SCHEMBL3664512 | 0.63 | AHR (0.43) | AHRTSHRGAAALDH1A1 | |
| SCHEMBL20620683 | 0.62 | HPGD (0.42) | TSHRGAAALDH1A1 | |
| SCHEMBL10809934 | 0.62 | AHR (0.35) | AHRTSHRALDH1A1 | |
| SCHEMBL30943277 | 0.61 | MEN1 (0.38) | AHRALDH1A1 | |
| SCHEMBL24567318 | 0.60 | EIF4A3 (0.34) | AHRALDH1A1 | |
| SCHEMBL22491181 | 0.60 | AHR (0.33) | AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| US-20160318917-A1 | NRF2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | AHR 32/4885TSHR 2353/4885GAA 2667/4885 |
| US-20160318917-A1 | NRF2 REGULATORS | NFE2L2, KEAP1, NQO1 | AHR 32/4885TSHR 2353/4885GAA 2667/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | AHR 795/4885TSHR 4121/4885GAA 2786/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | AHR 32/4885TSHR 2353/4885GAA 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.